Events

View All

    AACR 2025 Posters

    April 25, 2025
    Share on:

    April 25-30, 2025
    McCormick Place Convention Center, Chicago, IL

    We're thrilled to announce that we'll be exhibiting at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025! Join us from April 25th – 30th in Chicago, Illinois, at this prestigious event where biotechnology companies showcase groundbreaking advancements. With unparalleled networking opportunities, this conference unites innovators, investors, and biopharmaceutical leaders to drive collaboration and accelerate progress in the life sciences industry. We look forward to connecting with you there!

    Access all of Biocytogen's AACR posters below—download now!

    REQUEST POSTER SCHEDULE A MEETING WITH US

    AACR 2025 Poster Presentations

    BioMice - Preclinical Humanized Mouse Models
    Target Related Models Poster Title
    IL12Rβ1; IL12Rβ2 B-hIL12RB1/hIL12RB2 mice ad A novel IL12Rβ1 and IL12Rβ2 humanized mouse model for preclinical toxicity evaluation of human IL-12 analogs
    IL-2RB; IL-2RG; IL-15; IL-15RA B-hIL-2RB/hIL-2RG/hIL-15/hIL-15RA mice A novel IL2 and IL15 receptor humanized mouse model for preclinical research
    Flt3 B-NDG Flt3 KO mice An in vivo humanized mouse model for human dendritic cell reconstitution to evaluate efficacy of tumor immunotherapy by B-NDG Flt3 KO mice
    CD3; HER2 B-hCD3E/hHER2 mice; B-NDG mice Preclinical syngeneic model and xenograft model for evaluating CD3/HER2 bispecific antibody therapy
    TRBC1; TRBC2 B-hTRBC1/hTRBC2 mice Development and validation of a novel TRBC1 and TRBC2 humanized mice model for T cell activation
    PD-1; IL12Rβ1; IL12Rβ2 B-hPD-1 plus/hIL12RB1/hIL12RB2 mice A novel PD-1, IL12Rβ1 and IL12Rβ2 humanized mouse model for evaluating the combined efficacy of anti-tumor therapies:
    FcγRI; FcγRIIb; FcγRIII; FcγRIV; IL15 B-NDG hIL15, FcγR KO mice Development of a human immune system reconstituted mouse model without the function of FcγRs expressed on mouse innate immune cells
    GDF15 B-hGDF15 mice Humanized GDF15 model for simulating weight loss induced by GDF15 secretion in tumors
    HER2 B-hHER2 mice; B-h4-1BB/hHER2 mice; B-NDG mice Animal models for evaluating the efficacy of anti-human HER2 ADC alone or in combination with IO therapy
    HLA-A11.1 B-HLA-A11.1 mice Development and validation of humanized HLA-A11.1 mouse model for preclinical evaluation of novel peptide vaccines
    HLA-A2.1 B-HLA-A2.1 mice Utilizing a humanized HLA-A2.1 mouse model for non-clinical studies of mRNA vaccines
    C1Q B-hC1Q mice Generation of humanized C1Q mice for antibody-mediated CDC therapy research
    CRBN B-hCRBN mice The humanized CRBN mice model facilitates PROTACs studies based on CRBN ligands
    KIR; NKC B-hNKC/hKIR Mice NKC and KIR humanized mice: a powerful tool to develop NK-targeting drugs
    TNFR1; TNFR2; LTBR B-hTNFR2/hTNFR1/hLTBR mice Development of TNFR2, TNFR1 and LTBR humanized mouse model for evaluating anti-human LTBR antibodies
    CD3; DLL3 B-hCD3EDG mice; B-NDG mice Preclinical evaluation of CD3/DLL3 bispecific antibody in syngeneic and humanized mouse models for solid tumor treatment
    RenBiologics - Cutting-Edge Fully Human Antibody Assets
    Antibody Assets Platform Poster Title
    TCR-mimic antibodies RenTCR-mimic Development of fully human TCR-mimic antibodies targeting intracellular tumor antigens using humanized RenTCR-mimic transgenic mice
    DLL3xB7H3 bispecific ADC RenLite Bispecific antibody drug conjugates (bsADCs) targeting DLL3 and B7-H3 demonstrated potent anti-tumor activity in preclinical models of small cell lung cancer (SCLC)
    CD3×4-1BB trispecific antibody RenLite; RenNano The trispecific T cell engager platform enhances T cell function and therapeutic efficacy via integrated 4-1BB VHH antibody co-stimulation
    CDH3 ADC RenLite CDH3 knockout mouse platform BCG014: a CDH3-targeting ADC with a novel TOP1 inhibitor demonstrates robust anti-tumor efficacy in PDX models
    PTK7xTROP2 bispecific ADC RenLite BCG033: a first-in-class PTK7xTROP2 bispecific ADC demonstrating potent and broad efficacy in various preclinical models
    CTLA-4×OX40 bispecific antibody RenLite YH006: a next-generation CTLA-4×OX40 Treg antagonist, demonstrates superior tumor-infiltrating Treg-depletion efficacy and favorable manufacturability
    DLL3xSEZ6 bispecific ADC RenLite Preclinical study of bispecific antibody drug conjugates (bsADCs) targeting DLL3 and SEZ6 demonstrated potent anti-tumor activity in small cell lung cancer (SCLC) xenograft models
    N/A RenMice RenBiologics- a fully human antibody library generated by RenMice facilitates the development of antibody drugs
    VEGFA Hu-VHH antibody RenNano Discovery of a highly potent fully human VEGF VHH antibody from RenNano transgenic mice that exhibits a superior blocking activity on VEGF function